Skip to Content

Ustekinumab Dosage

Applies to the following strength(s): 45 mg/0.5 mL ; 90 mg/mL

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Psoriasis

100 kg (220 lbs) or less:
Initial dose: 45 mg subcutaneously once initially and 4 weeks later
Maintenance dose: 45 mg subcutaneously once every 12 weeks

Greater than 100 kg (220 lbs):
Initial dose: 90 mg subcutaneously once initially and 4 weeks later
Maintenance dose: 90 mg subcutaneously once every 12 weeks

Comment:
-In subjects weighing greater than 100 kg, 45 mg was also shown to be effective. However, 90 mg resulted in greater efficacy.

Use: For the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Usual Adult Dose for Psoriatic Arthritis

Initial dose: 45 mg subcutaneously once initially and 4 weeks later
Maintenance dose: 45 mg subcutaneously once every 12 weeks

For patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg (220 lbs):
Initial dose: 90 mg subcutaneously once initially and 4 weeks later
Maintenance dose: 90 mg subcutaneously once every 12 weeks

Use: For the treatment of adult patients (18 years or older) with active psoriatic arthritis. This drug can be used alone or in combination with methotrexate (MTX).

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US REMS: The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for this drug. It includes a communication plan. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This drug is for subcutaneous injection only.
-If possible, areas of skin that show effects of psoriasis should not be selected as sites for administration.
-After training and if deemed appropriate, patients may self-administer injections following the directions provided in the patient information leaflet; however, the clinician should ensure appropriate follow-up of patients.

Storage requirements:
-Refrigerate (2 C to 8 C); do not freeze.
-Keep prefilled syringe in outer carton to protect from light.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

General:
-Each prefilled syringe is for single use only; any unused product should be disposed of in accordance with local guidelines.

Hide